Pharmaceutical Continuous Manufacturing Market Synopsis
The Global Pharmaceutical Continuous Manufacturing Market size was reasonably estimated to be approximately USD 1,330.56 Million in 2022 and is poised to generate revenue over USD 3,562.34 Million by the end of 2030, projecting a CAGR of around 13.10% from 2022 to 2030.
Continuous Manufacturing is also known as continuous flow chemistry. Continuous manufacturing is an advanced manufacturing approach with the potential to increase the consistency and quality of pharmaceuticals while lowering their cost. The manufacturing processes on this production line are fully integrated and run in a continuous flow.
- Pharmaceutical continuous manufacturing is an end-to-end method of producing medications that improve the consistency and quality of a variety of innovative pharmaceuticals and vaccines while requiring little capital outlay. It operates in a continuous flow as opposed to batch processing, is simpler to scale, gives producers more control and a higher level of automation, and forgoes manual interaction.
- Effective medicines are produced in small, closed units using continuous pharmaceutical manufacturing technology using automation. Therefore, it requires less manual intervention. A continuous process combines production steps that are usually performed as a batch process. All this contributes to the continuous utilization of industrial capacity. Fluctuations in production are reduced, yields are improved, and operating and equipment costs are reduced. Because of these advantages, the approach is steadily gaining popularity.
- Pharmaceutical continuous manufacturing also helps to reduce the time it takes to formulate medicines, the danger of human mistakes, monitor production processes, and enhance product quality to comply with regulatory standards. In order to create active pharmaceutical ingredients (API) and medicines, pharmaceutical corporations and contract manufacturing organizations (CMOs) frequently use this technology. Integrated, semi-continuous, and control types are the ones that are now offered.
The Pharmaceutical Continuous Manufacturing Market Trend Analysis
The Technological Advancement in Continuous Manufacturing System
- Significant technological advancements such as rapid automation in drug manufacturing methodology and extensive integration of artificial intelligence solutions are contributing to the growth of the market. Other factors such as significant advances in the pharmaceutical sector, ongoing recent development activities and awareness of the availability of Food and Drug Administration (FDA) approved drugs drive the market growth.
- One of the major factors driving the continuous drug production market is the growing demand for efficient drug production systems that can produce a variety of potent biologics at lower costs. The reason for this is the ever-increasing shortage of medicines and the prevalence of several chronic diseases in various parts of the world. In addition, growing health concerns, especially during the outbreak of the coronavirus disease (COVID-19) pandemic, have encouraged pharmaceutical companies to use continuous production methods to produce new vaccines, acting as another growth engine.
Increasing Investments in Process Automation in Pharmaceutical Sectors
- As the demand for new drugs increases, manufacturers are changing their production methods to increase productivity. Continuous production has several advantages, including greater efficiency, and productivity made possible by the linking of unit operations. Improved product quality and safety enabled by continuous automated process monitoring. It helps reduce environmental impact by reducing waste due to high reaction efficiency and space-saving due to the compact size of the kits.
- All these factors support the adoption of automated production systems in the pharmaceutical industry. In addition, many leading pharmaceutical manufacturers are expanding their API business in developing countries, which will further support market expansion during the forecast period. Many pharmaceutical companies are investing in this sector creating a growth opportunity for market expansion. For instance, Thermo Fisher will invest USD 82.5 million to increase production capacity at its biological drug substance manufacturing facility in St. Louis. The investment will increase the company's entire manufacturing capacity two-fold, serving both short- and long-term COVID-19 requirements.
- pharmaceutical manufacturing systems reduce production variability, improve yields, and lower operational and equipment costs, which are expected to create profitable opportunities for market expansion. For instance, in 2019, Caperion launched the next generation of high-precision vibrating feeder technology with higher precision and faster product changeover.
Segmentation Analysis of The Pharmaceutical Continuous Manufacturing Market
Pharmaceutical Continuous Manufacturing market segments cover the Product Type, Formulation, Application, Distribution Channels, and End User. By Formulation, the Solid Formulation segment is anticipated to dominate the Market Over the Forecast period.
- Solid formulations dominated during the forecast period. As of November 2018, five fixed-dose drugs have received FDA approval and are in continuous production. This led to the dominance of this segment. In addition, companies such as Merck, GEA Group, and Pfizer are developing new products such as Pfizer's Portable Continuous Miniaturized and Modular System (PCMM), which is expected to increase the use of this manufacturing process in fixed-dose manufacturing.
- In addition, as many oral solid dosage products are now off-patent and new oral solid dosage forms are manufactured in smaller quantities, the pharmaceutical industry increasingly requires continuous manufacturing processes for manufacturing solid dosage products. The adoption of continuous manufacturing processes for liquid dosage forms is slow compared to solid dosage forms. Due to the growth of continuous production processes for solid dosage forms, manufacturers and companies offering products in this segment are receptive to the development of production methods for their liquid dosage forms.
Regional Analysis of The Pharmaceutical Continuous Manufacturing Market
North America is Expected to Dominate the Market Over the Forecast Period.
- Due to the presence of major market players and the availability of advanced technology North America is excepted to dominate the market. In addition, favorable regulatory infrastructure and high demand for medicines are anticipated to drive market growth in the region. Additionally, high R&D investments by pharmaceutical and biotechnology companies in the region are anticipated to boost market growth in the region. For instance, in June 2022, National Resilience Inc. raised $625 million in Series D funding, which would be used in part for the continuous production of biological substances.
- Also, strategies of players in emerging markets such as collaboration to gain more market share are expected to boost the market growth in this region. For instance, Agilent partnered with APC Ltd to combine their technologies to provide customers with unique workflows that support automated process analysis using liquid chromatography. Moreover, increasing support from government organizations is expected to stimulate the growth of the market under study in this region.
- The largest share of the regional market was accounted for by growing end users who have implemented or plan to implement CM technology in their facilities in North American countries. In addition, regulators play a key role in driving revenue growth in this industry.
Covid-19 Impact Analysis on Pharmaceutical Continuous Manufacturing Market
- The coronavirus epidemic has affected the market for continuous production of pharmaceuticals, as the supply of raw materials and active pharmaceutical ingredients has stopped. Consequently, a lack of raw materials and packaging materials or temporary disruptions hinder the growth of the market. In addition, the sectors faced fewer restrictions during the pandemic period due to their importance.
- However, the COVID-19 pandemic has had a positive impact on the growth of the global pharmaceutical continuous manufacturing market. The demand for existing drugs and new active ingredients to aid in the treatment of COVID-19 has increased the demand for continuous drug production. In addition, governments around the world require an increase in the production process of drugs during the pandemic, which again supported the growth of the market. Many drug manufacturers were completely shut down during the pandemic.
Top Key Players Covered in The Pharmaceutical Continuous Manufacturing Market
- Hosokawa Micron Group (US)
- Robert Bosch GmbH (Germany)
- Thermo Fisher Scientific Inc (US)
- GEA Group (Germany)
- Coperion GmbH (Netherlands)
- Baker Perkins (UK)
- Scott Equipment (US)
- Eli Lilly (US)
- Chemtrix (Netherland)
- Novartis AG (Switzerland)
- Siemens (Germany)
- Glatt GmbH (Germany), and Other Major Players
Key Industry Developments in the Pharmaceutical Continuous Manufacturing Market
In December 2022, The U.S. Pharmacopeia (USP) announced the opening of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia as part of its launch of a suite of R&D analytical solutions. These analytical lab services support the efforts of drug manufacturers seeking to adopt advanced manufacturing technologies including pharmaceutical continuous manufacturing (PCM) as one way to help increase geographic diversity in pharmaceutical manufacturing and support medicines supply chain resilience.
In March 2022, Phlow Corp, a United States essential medicines public benefit company entered alliances with both Virginia Commonwealth University (VCU) Medicines for All Institute and AMPAC fine chemicals to provide contract continuous manufacturing research and development services for small molecule pharmaceutical products.
Global Pharmaceutical Continuous Manufacturing Market |
|||
Base Year: |
2021 |
Forecast Period: |
2022-2030 |
Historical Data: |
2016 to 2020 |
Market Size in 2022: |
USD 1,330.56 Mn. |
Forecast Period 2022-28 CAGR: |
13.10% |
Market Size in 2030: |
USD 3,562.34 Mn. |
|
By Product Type |
|
|
By Formulation |
|
||
By Application |
|
||
By Distribution Channel |
|
||
By End Users |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Product Type
3.2 By Formulation
3.3 By Application
3.4 By Distribution Channel
3.5 By End Users
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Pharmaceutical Continuous Manufacturing Market by Product Type
5.1 Pharmaceutical Continuous Manufacturing Market Overview Snapshot and Growth Engine
5.2 Pharmaceutical Continuous Manufacturing Market Overview
5.3 Integrated Systems
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Integrated Systems: Geographic Segmentation
5.4 Semi-Continuous Systems
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Semi-Continuous Systems: Geographic Segmentation
5.5 Controls
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Controls: Geographic Segmentation
Chapter 6: Pharmaceutical Continuous Manufacturing Market by Formulation
6.1 Pharmaceutical Continuous Manufacturing Market Overview Snapshot and Growth Engine
6.2 Pharmaceutical Continuous Manufacturing Market Overview
6.3 Solid Formulation
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Solid Formulation: Geographic Segmentation
6.4 Liquid & Semi-solid Formulation
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Liquid & Semi-solid Formulation: Geographic Segmentation
Chapter 7: Pharmaceutical Continuous Manufacturing Market by Application
7.1 Pharmaceutical Continuous Manufacturing Market Overview Snapshot and Growth Engine
7.2 Pharmaceutical Continuous Manufacturing Market Overview
7.3 API manufacturing
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size (2016-2030F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 API manufacturing: Geographic Segmentation
7.4 Final Drug Product Manufacturing
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size (2016-2030F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Final Drug Product Manufacturing: Geographic Segmentation
Chapter 8: Pharmaceutical Continuous Manufacturing Market by Distribution Channel
8.1 Pharmaceutical Continuous Manufacturing Market Overview Snapshot and Growth Engine
8.2 Pharmaceutical Continuous Manufacturing Market Overview
8.3 Hospital Pharmacy
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size (2016-2030F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 Hospital Pharmacy: Geographic Segmentation
8.4 Retail Pharmacy
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size (2016-2030F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Retail Pharmacy: Geographic Segmentation
8.5 Online Pharmacy
8.5.1 Introduction and Market Overview
8.5.2 Historic and Forecasted Market Size (2016-2030F)
8.5.3 Key Market Trends, Growth Factors and Opportunities
8.5.4 Online Pharmacy: Geographic Segmentation
Chapter 9: Pharmaceutical Continuous Manufacturing Market by End Users
9.1 Pharmaceutical Continuous Manufacturing Market Overview Snapshot and Growth Engine
9.2 Pharmaceutical Continuous Manufacturing Market Overview
9.3 Research & Development Departments
9.3.1 Introduction and Market Overview
9.3.2 Historic and Forecasted Market Size (2016-2030F)
9.3.3 Key Market Trends, Growth Factors and Opportunities
9.3.4 Research & Development Departments: Geographic Segmentation
9.4 Pharmaceutical Companies
9.4.1 Introduction and Market Overview
9.4.2 Historic and Forecasted Market Size (2016-2030F)
9.4.3 Key Market Trends, Growth Factors and Opportunities
9.4.4 Pharmaceutical Companies: Geographic Segmentation
9.5 CMO
9.5.1 Introduction and Market Overview
9.5.2 Historic and Forecasted Market Size (2016-2030F)
9.5.3 Key Market Trends, Growth Factors and Opportunities
9.5.4 CMO: Geographic Segmentation
Chapter 10: Company Profiles and Competitive Analysis
10.1 Competitive Landscape
10.1.1 Competitive Positioning
10.1.2 Pharmaceutical Continuous Manufacturing Sales and Market Share By Players
10.1.3 Industry BCG Matrix
10.1.4 Heat Map Analysis
10.1.5 Pharmaceutical Continuous Manufacturing Industry Concentration Ratio (CR5 and HHI)
10.1.6 Top 5 Pharmaceutical Continuous Manufacturing Players Market Share
10.1.7 Mergers and Acquisitions
10.1.8 Business Strategies By Top Players
10.2 HOSOKAWA MICRON GROUP
10.2.1 Company Overview
10.2.2 Key Executives
10.2.3 Company Snapshot
10.2.4 Operating Business Segments
10.2.5 Product Portfolio
10.2.6 Business Performance
10.2.7 Key Strategic Moves and Recent Developments
10.2.8 SWOT Analysis
10.3 ROBERT BOSCH GMBH
10.4 THERMO FISHER SCIENTIFIC INC
10.5 GEA GROUP
10.6 COPERION GMBH
10.7 BAKER PERKINS
10.8 SCOTT EQUIPMENT
10.9 ELI LILLY
10.10 CHEMTRIX
10.11 NOVARTIS AG
10.12 SIEMENS
10.13 GLATT GMBH
10.14 OTHER MAJOR PLAYERS
Chapter 11: Global Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
11.1 Market Overview
11.2 Historic and Forecasted Market Size By Product Type
11.2.1 Integrated Systems
11.2.2 Semi-Continuous Systems
11.2.3 Controls
11.3 Historic and Forecasted Market Size By Formulation
11.3.1 Solid Formulation
11.3.2 Liquid & Semi-solid Formulation
11.4 Historic and Forecasted Market Size By Application
11.4.1 API manufacturing
11.4.2 Final Drug Product Manufacturing
11.5 Historic and Forecasted Market Size By Distribution Channel
11.5.1 Hospital Pharmacy
11.5.2 Retail Pharmacy
11.5.3 Online Pharmacy
11.6 Historic and Forecasted Market Size By End Users
11.6.1 Research & Development Departments
11.6.2 Pharmaceutical Companies
11.6.3 CMO
Chapter 12: North America Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Product Type
12.4.1 Integrated Systems
12.4.2 Semi-Continuous Systems
12.4.3 Controls
12.5 Historic and Forecasted Market Size By Formulation
12.5.1 Solid Formulation
12.5.2 Liquid & Semi-solid Formulation
12.6 Historic and Forecasted Market Size By Application
12.6.1 API manufacturing
12.6.2 Final Drug Product Manufacturing
12.7 Historic and Forecasted Market Size By Distribution Channel
12.7.1 Hospital Pharmacy
12.7.2 Retail Pharmacy
12.7.3 Online Pharmacy
12.8 Historic and Forecasted Market Size By End Users
12.8.1 Research & Development Departments
12.8.2 Pharmaceutical Companies
12.8.3 CMO
12.9 Historic and Forecast Market Size by Country
12.9.1 US
12.9.2 Canada
12.9.3 Mexico
Chapter 13: Eastern Europe Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Product Type
13.4.1 Integrated Systems
13.4.2 Semi-Continuous Systems
13.4.3 Controls
13.5 Historic and Forecasted Market Size By Formulation
13.5.1 Solid Formulation
13.5.2 Liquid & Semi-solid Formulation
13.6 Historic and Forecasted Market Size By Application
13.6.1 API manufacturing
13.6.2 Final Drug Product Manufacturing
13.7 Historic and Forecasted Market Size By Distribution Channel
13.7.1 Hospital Pharmacy
13.7.2 Retail Pharmacy
13.7.3 Online Pharmacy
13.8 Historic and Forecasted Market Size By End Users
13.8.1 Research & Development Departments
13.8.2 Pharmaceutical Companies
13.8.3 CMO
13.9 Historic and Forecast Market Size by Country
13.9.1 Bulgaria
13.9.2 The Czech Republic
13.9.3 Hungary
13.9.4 Poland
13.9.5 Romania
13.9.6 Rest of Eastern Europe
Chapter 14: Western Europe Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Product Type
14.4.1 Integrated Systems
14.4.2 Semi-Continuous Systems
14.4.3 Controls
14.5 Historic and Forecasted Market Size By Formulation
14.5.1 Solid Formulation
14.5.2 Liquid & Semi-solid Formulation
14.6 Historic and Forecasted Market Size By Application
14.6.1 API manufacturing
14.6.2 Final Drug Product Manufacturing
14.7 Historic and Forecasted Market Size By Distribution Channel
14.7.1 Hospital Pharmacy
14.7.2 Retail Pharmacy
14.7.3 Online Pharmacy
14.8 Historic and Forecasted Market Size By End Users
14.8.1 Research & Development Departments
14.8.2 Pharmaceutical Companies
14.8.3 CMO
14.9 Historic and Forecast Market Size by Country
14.9.1 Germany
14.9.2 UK
14.9.3 France
14.9.4 Netherlands
14.9.5 Italy
14.9.6 Russia
14.9.7 Spain
14.9.8 Rest of Western Europe
Chapter 15: Asia Pacific Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
15.1 Key Market Trends, Growth Factors and Opportunities
15.2 Impact of Covid-19
15.3 Key Players
15.4 Key Market Trends, Growth Factors and Opportunities
15.4 Historic and Forecasted Market Size By Product Type
15.4.1 Integrated Systems
15.4.2 Semi-Continuous Systems
15.4.3 Controls
15.5 Historic and Forecasted Market Size By Formulation
15.5.1 Solid Formulation
15.5.2 Liquid & Semi-solid Formulation
15.6 Historic and Forecasted Market Size By Application
15.6.1 API manufacturing
15.6.2 Final Drug Product Manufacturing
15.7 Historic and Forecasted Market Size By Distribution Channel
15.7.1 Hospital Pharmacy
15.7.2 Retail Pharmacy
15.7.3 Online Pharmacy
15.8 Historic and Forecasted Market Size By End Users
15.8.1 Research & Development Departments
15.8.2 Pharmaceutical Companies
15.8.3 CMO
15.9 Historic and Forecast Market Size by Country
15.9.1 China
15.9.2 India
15.9.3 Japan
15.9.4 South Korea
15.9.5 Malaysia
15.9.6 Thailand
15.9.7 Vietnam
15.9.8 The Philippines
15.9.9 Australia
15.9.10 New Zealand
15.9.11 Rest of APAC
Chapter 16: Middle East & Africa Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
16.1 Key Market Trends, Growth Factors and Opportunities
16.2 Impact of Covid-19
16.3 Key Players
16.4 Key Market Trends, Growth Factors and Opportunities
16.4 Historic and Forecasted Market Size By Product Type
16.4.1 Integrated Systems
16.4.2 Semi-Continuous Systems
16.4.3 Controls
16.5 Historic and Forecasted Market Size By Formulation
16.5.1 Solid Formulation
16.5.2 Liquid & Semi-solid Formulation
16.6 Historic and Forecasted Market Size By Application
16.6.1 API manufacturing
16.6.2 Final Drug Product Manufacturing
16.7 Historic and Forecasted Market Size By Distribution Channel
16.7.1 Hospital Pharmacy
16.7.2 Retail Pharmacy
16.7.3 Online Pharmacy
16.8 Historic and Forecasted Market Size By End Users
16.8.1 Research & Development Departments
16.8.2 Pharmaceutical Companies
16.8.3 CMO
16.9 Historic and Forecast Market Size by Country
16.9.1 Turkey
16.9.2 Bahrain
16.9.3 Kuwait
16.9.4 Saudi Arabia
16.9.5 Qatar
16.9.6 UAE
16.9.7 Israel
16.9.8 South Africa
Chapter 17: South America Pharmaceutical Continuous Manufacturing Market Analysis, Insights and Forecast, 2016-2030
17.1 Key Market Trends, Growth Factors and Opportunities
17.2 Impact of Covid-19
17.3 Key Players
17.4 Key Market Trends, Growth Factors and Opportunities
17.4 Historic and Forecasted Market Size By Product Type
17.4.1 Integrated Systems
17.4.2 Semi-Continuous Systems
17.4.3 Controls
17.5 Historic and Forecasted Market Size By Formulation
17.5.1 Solid Formulation
17.5.2 Liquid & Semi-solid Formulation
17.6 Historic and Forecasted Market Size By Application
17.6.1 API manufacturing
17.6.2 Final Drug Product Manufacturing
17.7 Historic and Forecasted Market Size By Distribution Channel
17.7.1 Hospital Pharmacy
17.7.2 Retail Pharmacy
17.7.3 Online Pharmacy
17.8 Historic and Forecasted Market Size By End Users
17.8.1 Research & Development Departments
17.8.2 Pharmaceutical Companies
17.8.3 CMO
17.9 Historic and Forecast Market Size by Country
17.9.1 Brazil
17.9.2 Argentina
17.9.3 Rest of SA
Chapter 18 Investment Analysis
Chapter 19 Analyst Viewpoint and Conclusion
Global Pharmaceutical Continuous Manufacturing Market |
|||
Base Year: |
2021 |
Forecast Period: |
2022-2030 |
Historical Data: |
2016 to 2020 |
Market Size in 2022: |
USD 1,330.56 Mn. |
Forecast Period 2022-28 CAGR: |
13.10% |
Market Size in 2030: |
USD 3,562.34 Mn. |
|
By Product Type |
|
|
By Formulation |
|
||
By Application |
|
||
By Distribution Channel |
|
||
By End Users |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET COMPETITIVE RIVALRY
TABLE 005. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET THREAT OF NEW ENTRANTS
TABLE 006. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET THREAT OF SUBSTITUTES
TABLE 007. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BY PRODUCT TYPE
TABLE 008. INTEGRATED SYSTEMS MARKET OVERVIEW (2016-2030)
TABLE 009. SEMI-CONTINUOUS SYSTEMS MARKET OVERVIEW (2016-2030)
TABLE 010. CONTROLS MARKET OVERVIEW (2016-2030)
TABLE 011. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BY FORMULATION
TABLE 012. SOLID FORMULATION MARKET OVERVIEW (2016-2030)
TABLE 013. LIQUID & SEMI-SOLID FORMULATION MARKET OVERVIEW (2016-2030)
TABLE 014. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BY APPLICATION
TABLE 015. API MANUFACTURING MARKET OVERVIEW (2016-2030)
TABLE 016. FINAL DRUG PRODUCT MANUFACTURING MARKET OVERVIEW (2016-2030)
TABLE 017. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BY DISTRIBUTION CHANNEL
TABLE 018. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2030)
TABLE 019. RETAIL PHARMACY MARKET OVERVIEW (2016-2030)
TABLE 020. ONLINE PHARMACY MARKET OVERVIEW (2016-2030)
TABLE 021. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET BY END USERS
TABLE 022. RESEARCH & DEVELOPMENT DEPARTMENTS MARKET OVERVIEW (2016-2030)
TABLE 023. PHARMACEUTICAL COMPANIES MARKET OVERVIEW (2016-2030)
TABLE 024. CMO MARKET OVERVIEW (2016-2030)
TABLE 025. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 026. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 027. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 028. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 029. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 030. N PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 031. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 032. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 033. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 034. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 035. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 036. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 037. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 038. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 039. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 040. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 041. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 042. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 043. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 044. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 045. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 046. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 047. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 048. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 049. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 050. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 051. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 052. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 053. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 054. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 055. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT TYPE (2016-2030)
TABLE 056. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FORMULATION (2016-2030)
TABLE 057. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION (2016-2030)
TABLE 058. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL (2016-2030)
TABLE 059. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USERS (2016-2030)
TABLE 060. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY (2016-2030)
TABLE 061. HOSOKAWA MICRON GROUP: SNAPSHOT
TABLE 062. HOSOKAWA MICRON GROUP: BUSINESS PERFORMANCE
TABLE 063. HOSOKAWA MICRON GROUP: PRODUCT PORTFOLIO
TABLE 064. HOSOKAWA MICRON GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. ROBERT BOSCH GMBH: SNAPSHOT
TABLE 065. ROBERT BOSCH GMBH: BUSINESS PERFORMANCE
TABLE 066. ROBERT BOSCH GMBH: PRODUCT PORTFOLIO
TABLE 067. ROBERT BOSCH GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. THERMO FISHER SCIENTIFIC INC: SNAPSHOT
TABLE 068. THERMO FISHER SCIENTIFIC INC: BUSINESS PERFORMANCE
TABLE 069. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 070. THERMO FISHER SCIENTIFIC INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. GEA GROUP: SNAPSHOT
TABLE 071. GEA GROUP: BUSINESS PERFORMANCE
TABLE 072. GEA GROUP: PRODUCT PORTFOLIO
TABLE 073. GEA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. COPERION GMBH: SNAPSHOT
TABLE 074. COPERION GMBH: BUSINESS PERFORMANCE
TABLE 075. COPERION GMBH: PRODUCT PORTFOLIO
TABLE 076. COPERION GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. BAKER PERKINS: SNAPSHOT
TABLE 077. BAKER PERKINS: BUSINESS PERFORMANCE
TABLE 078. BAKER PERKINS: PRODUCT PORTFOLIO
TABLE 079. BAKER PERKINS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. SCOTT EQUIPMENT: SNAPSHOT
TABLE 080. SCOTT EQUIPMENT: BUSINESS PERFORMANCE
TABLE 081. SCOTT EQUIPMENT: PRODUCT PORTFOLIO
TABLE 082. SCOTT EQUIPMENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. ELI LILLY: SNAPSHOT
TABLE 083. ELI LILLY: BUSINESS PERFORMANCE
TABLE 084. ELI LILLY: PRODUCT PORTFOLIO
TABLE 085. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. CHEMTRIX: SNAPSHOT
TABLE 086. CHEMTRIX: BUSINESS PERFORMANCE
TABLE 087. CHEMTRIX: PRODUCT PORTFOLIO
TABLE 088. CHEMTRIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. NOVARTIS AG: SNAPSHOT
TABLE 089. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 090. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 091. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. SIEMENS: SNAPSHOT
TABLE 092. SIEMENS: BUSINESS PERFORMANCE
TABLE 093. SIEMENS: PRODUCT PORTFOLIO
TABLE 094. SIEMENS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 094. GLATT GMBH: SNAPSHOT
TABLE 095. GLATT GMBH: BUSINESS PERFORMANCE
TABLE 096. GLATT GMBH: PRODUCT PORTFOLIO
TABLE 097. GLATT GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 097. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 098. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 099. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 100. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY PRODUCT TYPE
FIGURE 012. INTEGRATED SYSTEMS MARKET OVERVIEW (2016-2030)
FIGURE 013. SEMI-CONTINUOUS SYSTEMS MARKET OVERVIEW (2016-2030)
FIGURE 014. CONTROLS MARKET OVERVIEW (2016-2030)
FIGURE 015. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY FORMULATION
FIGURE 016. SOLID FORMULATION MARKET OVERVIEW (2016-2030)
FIGURE 017. LIQUID & SEMI-SOLID FORMULATION MARKET OVERVIEW (2016-2030)
FIGURE 018. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY APPLICATION
FIGURE 019. API MANUFACTURING MARKET OVERVIEW (2016-2030)
FIGURE 020. FINAL DRUG PRODUCT MANUFACTURING MARKET OVERVIEW (2016-2030)
FIGURE 021. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 022. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2030)
FIGURE 023. RETAIL PHARMACY MARKET OVERVIEW (2016-2030)
FIGURE 024. ONLINE PHARMACY MARKET OVERVIEW (2016-2030)
FIGURE 025. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY END USERS
FIGURE 026. RESEARCH & DEVELOPMENT DEPARTMENTS MARKET OVERVIEW (2016-2030)
FIGURE 027. PHARMACEUTICAL COMPANIES MARKET OVERVIEW (2016-2030)
FIGURE 028. CMO MARKET OVERVIEW (2016-2030)
FIGURE 029. NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
FIGURE 030. EASTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
FIGURE 031. WESTERN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
FIGURE 032. ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
FIGURE 033. MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
FIGURE 034. SOUTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OVERVIEW BY COUNTRY (2016-2030)
Frequently Asked Questions :
The forecast period in the Pharmaceutical Continuous Manufacturing Market research report is 2022-2028.
Hosokawa Micron Group (US), Robert Bosch GmbH (Germany), Thermo Fisher Scientific Inc (US), GEA Group (Germany), Coperion GmbH (Netherland), Baker Perkins (UK), Scott Equipment (US), Eli Lilly (US), Chemtrix (Netherland), Novartis AG (Switzerland), Siemens (Germany), Glatt GmbH (Germany), and Other Major Players
The Pharmaceutical Continuous Manufacturing Market is segmented into Product Type, Formulation, Application, Distribution Channels, End-user, and region. By Product Type, the market is categorized into Integrated Systems, Semi-Continuous Systems, and Controls. By, Formulation, the market is categorized into Solid Formulation, Liquid, and Semi-solid Formulation. By Application, the market is categorized into API manufacturing, Final Drug Product Manufacturing. By Distribution Channel, the market is categorized into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. By End-user, the market is categorized into Research and Development Departments, Pharmaceutical Companies, and CMO. By region, it is analyzed across North America (US, Canada, Mexico), Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Continuous Manufacturing is also known as continuous flow chemistry. Continuous manufacturing is an advanced manufacturing approach with the potential to increase the consistency and quality of pharmaceuticals while lowering their cost. The manufacturing processes on this production line are fully integrated and run in a continuous flow. Pharmaceutical continuous manufacturing is an end-to-end method of producing medications that improve the consistency and quality of a variety of innovative pharmaceuticals and vaccines while requiring little capital outlay.
The Global Pharmaceutical Continuous Manufacturing Market size was reasonably estimated to be approximately USD 1,330.56 Million in 2022 and is poised to generate revenue over USD 3,562.34 Million by the end of 2030, projecting a CAGR of around 13.10% from 2022 to 2030.